Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 3/20 | 0.34 |
| ▸ | FABP4 | P15090 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CMKLR1 | Q99788 | 9/20 | 0.32 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132094 | 0.84 | FABP3 (0.35) | FABP3FABP4ADORA1GCGRPTGS2 | |
| SCHEMBL1131833 | 0.80 | MDM2 (0.47) | FABP3FABP4CMKLR1MDM2BCL2 | |
| SCHEMBL1131835 | 0.80 | MDM2 (0.47) | FABP3FABP4CMKLR1MDM2BCL2 | |
| SCHEMBL1132019 | 0.77 | PTGS2 (0.40) | FABP3FABP4PTGS2CMKLR1APLNR | |
| SCHEMBL1132021 | 0.77 | PTGS2 (0.40) | FABP3FABP4PTGS2CMKLR1APLNR | |
| SCHEMBL1131567 | 0.77 | CMKLR1 (0.39) | FABP3FABP4GCGRCMKLR1FAAH | |
| SCHEMBL1131986 | 0.76 | CMKLR1 (0.36) | FABP3FABP4GCGRCMKLR1FAAH | |
| SCHEMBL1132134 | 0.69 | MDM2 (0.63) | FABP3FABP4CMKLR1MDM2BCL2 | |
| SCHEMBL1131946 | 0.66 | FAAH (0.54) | FABP3FABP4CMKLR1MDM2BCL2 | |
| SCHEMBL1131277 | 0.66 | MDM2 (0.48) | FABP3FABP4GCGRCMKLR1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | claimed |
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |